Contributions
Abstract: EP1570
Type: Poster Sessions
Abstract Category: Pathology and pathogenesis of MS - Biomarkers
Background: Anti-alpha-glucose IgM antibodies (gMS-Classifier1) have been proposed as biomarkers in multiple sclerosis (MS). There are hints of gMS-Classifier1 as predictors of expanded disability status scale (EDSS) progression in relapsing remitting multiple sclerosis.
Objective: The aim of this study was to test the ability of the gMS-Classifier1 to predict disability progression measured by changes in the EDSS score in MS patients with long-term follow-up.
Methods: Four Multiple Sclerosis centers collected blood samples and clinical data of patients with a final diagnosis of clinically isolated syndrome (CIS), relapsing remitting MS (RRMS) or secondary progressive MS (SPMS) between 1993 and 2007. Disability progression was defined as sustained progression of at least 1.0 EDSS point over the baseline EDSS. Serum samples (n=358) were analysed for different anti-glycan antibodies. If one of the four antibodies was above the cut off value, patients were considered positive for the gMS-Classifier1. We explored the association of gMS-Classifier1 status with EDSS progression.
Results: gMS-Classifier1 status at baseline did not predict EDSS progression during follow-up.
Conclusions: The gMS-Classifier1 may not have any predictive value for disability progression in MS.
Disclosure: Johannis A. van Rossum reports no conflicts of interest
Peter N. Riskind reports no conflicts of interest
Luisa M. Villar received payment for lecturing or travel expenses or research Grants or consultancyfrom Merck-Serono, Biogen, Sanofi-Genzyme, Roche, and Novartis.
Mark S. Freedman received educational grants of Genzyme Canada, honoraria or consultation fees of Actelion, BayerHealthcare, BiogenIdec, Chugai, Clene Nanomedicine, EMD Canada, Genzyme, Merck Serono, Novartis, Hoffman La-Roche, Sanofi-Aventis, Teva Canada Innovation. Is member of a company advisory board, board of directors or other similar group of Actelion, BayerHealthcare, BiogenIdec, Clene Nanomedicine, Hoffman La-Roche, Merck Serono, MedDay, Novartis, Sanofi-Aventis and participates in a company sponsored speaker's bureau of Sanofi-Genzyme
Charlotte Teunissen served on the advisory board of Fujirebio and Roche, received research consumables from Euroimmun, IBL, Fujirebio, Invitrogen, and Meso Scale Discovery, and performed contract research for IBL, Shire, Boehringer, Roche, and Probiodrug
Joep Killestein consulted for Novartis, Merck Serono, Bioven, Genzyme, Teva, and Roche; received speaker honoraria from Biogen, Novartis, Teva, Merck Serono, and Roche; is the editor for the official scientific journal of the Dutch Society of Neurology, The Dutch Society of Neurosurgeons, and the Society of Flemish Neurologists; serves on the editorial board of MS Journal; and received research support from Schering AG, Biogen Idec, Merck Serono, Teva, Genzyme, Novartis, and Roche. The VUmc MS Center Amsterdam has received financial support for research activities from Bayer Schering Pharma, Biogen, Roche, GlaxoSmithKline, Merck Serono, Genzyme, Novartis, and Teva
Abstract: EP1570
Type: Poster Sessions
Abstract Category: Pathology and pathogenesis of MS - Biomarkers
Background: Anti-alpha-glucose IgM antibodies (gMS-Classifier1) have been proposed as biomarkers in multiple sclerosis (MS). There are hints of gMS-Classifier1 as predictors of expanded disability status scale (EDSS) progression in relapsing remitting multiple sclerosis.
Objective: The aim of this study was to test the ability of the gMS-Classifier1 to predict disability progression measured by changes in the EDSS score in MS patients with long-term follow-up.
Methods: Four Multiple Sclerosis centers collected blood samples and clinical data of patients with a final diagnosis of clinically isolated syndrome (CIS), relapsing remitting MS (RRMS) or secondary progressive MS (SPMS) between 1993 and 2007. Disability progression was defined as sustained progression of at least 1.0 EDSS point over the baseline EDSS. Serum samples (n=358) were analysed for different anti-glycan antibodies. If one of the four antibodies was above the cut off value, patients were considered positive for the gMS-Classifier1. We explored the association of gMS-Classifier1 status with EDSS progression.
Results: gMS-Classifier1 status at baseline did not predict EDSS progression during follow-up.
Conclusions: The gMS-Classifier1 may not have any predictive value for disability progression in MS.
Disclosure: Johannis A. van Rossum reports no conflicts of interest
Peter N. Riskind reports no conflicts of interest
Luisa M. Villar received payment for lecturing or travel expenses or research Grants or consultancyfrom Merck-Serono, Biogen, Sanofi-Genzyme, Roche, and Novartis.
Mark S. Freedman received educational grants of Genzyme Canada, honoraria or consultation fees of Actelion, BayerHealthcare, BiogenIdec, Chugai, Clene Nanomedicine, EMD Canada, Genzyme, Merck Serono, Novartis, Hoffman La-Roche, Sanofi-Aventis, Teva Canada Innovation. Is member of a company advisory board, board of directors or other similar group of Actelion, BayerHealthcare, BiogenIdec, Clene Nanomedicine, Hoffman La-Roche, Merck Serono, MedDay, Novartis, Sanofi-Aventis and participates in a company sponsored speaker's bureau of Sanofi-Genzyme
Charlotte Teunissen served on the advisory board of Fujirebio and Roche, received research consumables from Euroimmun, IBL, Fujirebio, Invitrogen, and Meso Scale Discovery, and performed contract research for IBL, Shire, Boehringer, Roche, and Probiodrug
Joep Killestein consulted for Novartis, Merck Serono, Bioven, Genzyme, Teva, and Roche; received speaker honoraria from Biogen, Novartis, Teva, Merck Serono, and Roche; is the editor for the official scientific journal of the Dutch Society of Neurology, The Dutch Society of Neurosurgeons, and the Society of Flemish Neurologists; serves on the editorial board of MS Journal; and received research support from Schering AG, Biogen Idec, Merck Serono, Teva, Genzyme, Novartis, and Roche. The VUmc MS Center Amsterdam has received financial support for research activities from Bayer Schering Pharma, Biogen, Roche, GlaxoSmithKline, Merck Serono, Genzyme, Novartis, and Teva